In an earlier study of previously untreated patients with chronic lymphocytic leukemia (CLL), we used a concomitant combination of chlorambucil and 2-chlorodeoxyadenosine and reported overall (OR) and complete (CR) remission rates of 80% and 20%, respectively. After a median follow-up of 5 years, more than 80% of the responders have had a relapse. In the current phase II study of 27 previously untreated patients with CLL, we used a sequential combination of six cycles of intravenous cyclophosphamide (1 g/m 2 ) plus oral prednisone (100 mg/m 2 per day for 5 days) followed by two to six cycles of 2-chlorodeoxyadenosine (5 mg/m 2 per day for 5 days). The OR and CR rates were 96% and 33%, respectively. After a median follow-up of 29 months, 35% of the responders have had a relapse. Progression-free survival was significantly better in CR patients than in those with partial remission. However, minimal residual disease was phenotypically detected in four of the nine CR patients. Despite the fact that the current OR and CR rates are superior to those seen in a historical cohort treated with a concomitant schedule, a longer follow-up period is needed to assess the durability of these remissions, and a controlled trial is necessary to estimate the impact on overall survival and toxicity. Leukemia (2001) 15, 1171-1175.
Introduction
The purine nucleoside analogs (PNA), including fludarabine (FAMP), 2-chlorodeoxyadenosine (2-CdA), and pentostatin, have all been shown to have substantial antitumor activity in B cell chronic lymphocytic leukemia (CLL). 1 The mechanism of action may involve both a direct interference with DNA synthesis 2 and the induction of apoptosis in resting lymphocytes. [3] [4] [5] [6] Based on efficacy and toxicity data from patients with relapsed or refractory CLL, [7] [8] [9] treatment with FAMP and 2-CdA was preferentially pursued in the setting of previously untreated disease. 10 In a randomized study comparing these two agents in low-grade non-Hodgkin's lymphoma, response rates and duration of remission were similar. 11 In CLL, the two agents have not been directly compared with each other. However, randomized studies have suggested superior complete (CR) and overall (OR) remission rates with FAMP (20-27% and 63-71%, respectively) compared with traditional alkylator-based chemotherapy (4-17% and 37-60%, respectively). 12, 13 Furthermore, the remissions with FAMP were more durable (25-32 vs 14-18 months). However, the apparent superiority of PNAs over conventional chemotherapy has not led to improved survival, and more than half of PNA responders have had a relapse within 3 years of initial therapy. 9, 14 One reasonable approach to improve treatment outcome is to combine a PNA with another effective treatment modality.
In 1994, we published the results of a phase I study showing that two 7-day infusion courses of 2-CdA at a dosage of 2 mg/m 2 per day may be safely combined with oral chlorambucil at 30 mg/m 2 every 2 weeks. 15 The North Central Cancer Treatment Group (NCCTG) has since been involved in a series of phase II treatment trials in previously untreated patients with CLL using a combination of a PNA and an alkylating agent. In the first of these treatment trials, a concomitant combination of 2-CdA and chlorambucil was used as described above. 16 The corresponding OR and CR rates, following strict response criteria, 17 were 80% and 20%, respectively. Although this combination chemotherapy was well tolerated, more than 80% of the responders (including all of those with CR) have had a relapse after a median follow-up of 5 years. To allow dose intensification, we subsequently developed a sequential combination treatment strategy using six cycles of intravenous cyclophosphamide (CTX) therapy combined with oral prednisone, followed by treatment with two to six courses of full-dose 2-CdA.
Materials and methods

Patients and measurement criteria
The study was commenced after approval by the Hematology Committee of the NCCTG and the institutional review boards of the participating institutions. Written informed consent was obtained from all patients. Diagnostic criteria, treatment indications, and response determinations were according to the revised guidelines submitted by the National Cancer Institute (NCI)-sponsored Working Group on CLL. 17 NCI common toxicity criteria were used to grade nonhematologic toxicity. In this particular study, we defined neutropenia as mild (absolute neutrophil count (ANC) 1000-1500/l), moderate (ANC 500-1000/l), or severe (ANC less than 500/l). Thrombocytopenia was also defined as mild (platelet count 50 000-100 000/l), moderate (platelet count 25 000-50 000/l), or severe (platelet count less than 20 000/l). The use of myeloid growth factors was not allowed. CLL B cells were studied for CD38 expression by flow cytometry and were designated CD38
+ if more than 20% of the cells expressed CD38. All patients underwent bone marrow examination at the time of entry into the study, and the study was repeated to confirm pathologic CR. Karyotypic analysis was performed in pre-and post-treatment marrow samples.
Treatment
The dosage and schedule of the treatment agents are outlined in Table 1 . Planned treatment started with a maximum of six cycles of CTX and prednisone in all patients (Table 1) . After 4 to 6 weeks of the last cycle of CTX and prednisone, patients with CR received two treatment cycles of full-dose 2-CdA ( Table 1) . Patients with either partial remission (PR) or stable disease after the last cycle of CTX and prednisone received two to six cycles of 2-CdA, depending on their response after the first two cycles of 2-CdA. The individual drug dosages were modified according to both severity and duration of thrombocytopenia and neutropenia. In general, treatment with CTX was held for 1 week in case of any degree of neutropenia and of mild thrombocytopenia. If moderate to severe neutropenia or thrombocytopenia persisted after 1 week of delay, the patient was taken off the study. Patients with mild degrees of cytopenia were allowed to continue treatment with a 50% reduction in dosage of CTX. Treatment with 2-CdA was also delayed for 1 week in the presence of cytopenia. However, if any degree of cytopenia lasted for more than 1 week, the patient was taken off the study.
Evaluation of minimal residual disease
Treatment effect was monitored by periodic physical examination, blood count evaluation, and bone marrow examination of patients with clinical and hematologic remission. In patients with pathologic CR, minimal residual disease was evaluated by dual-color flow cytometry using CD5, CD19, CD20, and immunoglobulin light chain markers, as previously described. 14, 18 Phenotypic CR was considered in the absence of light-chain restriction (kappa-to-lambda ratio of Ͻ3:1 and Ͼ1:2) among CD19 + cells and a CD20 + CD5 + /CD20 + ratio of less than 25%. 18, 19 
Statistical considerations
This trial used a Simon optimal two-stage study design 20 to assess the tumor response of this treatment regimen in patients with B CLL. The design has a type I error rate of 0.07 if the true response rate is 25% and 86% power for concluding that the regimen is promising if the true response rate is 50%. Ten patients were to be accrued in the first stage, with three or more responses (CR) required to continue on to the second stage of 15 additional patients. In the final analysis, at least 10 Table 1 Treatment dosage and schedule of sequential combination chemotherapy with cyclophosphamide (CTX) and prednisone followed by 2-chlorodeoxyadenosine (2-CdA) responses (CR) in the total 25 patients were to be considered evidence of promising activity and hence recommended for further study. Ninety-five percent confidence intervals for the response probability were calculated using methodology reported by Duffy and Santner. 21 Other methods were used to explore, in a hypothesis-generating manner, the nature of and relationships to response. Fisher's exact test was used to explore differences in response rates among categories of clinical stage, bone marrow infiltration pattern, and CD38 expression status. Because of the inherent inaccuracies in assessing CR rates, both response duration and progression-free survival were used to evaluate treatment efficacy. The distribution of time to progression from date of entry was estimated using the Kaplan-Meier method. 22 Response duration was calculated from the time of establishment of response to the time of relapse, in which patients were censored at the date of last known follow-up. Differences in the progression-free survival curves were assessed using the log-rank test.
Results
Between November 1996 and January 1998, 27 eligible patients were enrolled into the study from several NCCTG institutions. Table 2 illustrates the pretreatment characteristics of the 27 patients, including sex, age, clinical stage, bone marrow infiltration pattern, CD38 expression status, and cytogenetic findings. Twenty-four patients (89%) completed the initial six cycles of treatment with CTX and prednisone, and 21 patients (78%) received at least one cycle of treatment with 2-CdA. During the CTX phase of the study, eight patients (33%) had a treatment delay of 7 days or more. Nineteen patients received the second cycle of 2-CdA, and the total number of events with dose reductions including both CTX and 2-CdA was 11. Both treatment delays and dose reductions were due to cytopenias ( Table 3 ). The overall remission (OR) rate was 96% (CR = 33%, PR = 63%, including 26% nodular PR). (The 90% confidence interval for CR probability was 22% to 54%.) Best response was achieved only after administration of 2-CdA in 14 patients (52%). Minimal residual disease was detected by flow cytometry in four of the nine patients (44%) with CR and six of the seven (86%) with nodular PR.
After a median follow-up of 29 months, two patients (7%) have died, including one from progressive disease; the cause of death in the second patient was unknown. Nine patients (35%) have had a relapse, including one with CR (11%), three with nodular PR (43%), and five with non-nodular PR (60%). Median duration of remission was 19 months (range 1-38+) and was notably longer in patients with CR (31 months, range 14-37+) than in those with either nodular PR (19 months, range 6-29+) or non-nodular PR (4 months, range 1-38+). Accordingly, there was a significant progression-free survival 1173 CLL, chronic lymphocytic leukemia.
Table 3
Toxicity comparison between the current study (sequential cyclophosphamide + 2-chlorodeoxyadenosine) and the previous study (concomitant chlorambucil + 2-chlorodeoxyadenosine) advantage favoring CR (Figure 1) . The only three patients with trisomy 12 have had a sustained CR, nodular PR, or relapsed non-nodular PR. Type of response (CR vs nodular PR/nonnodular PR) was not significantly influenced by clinical stage, bone marrow infiltration pattern, or the percentage of CLL cells that expressed CD38.
Nonhematologic grade 3 or 4 toxicity was observed during the treatment trial and included infection (four patients), congestive heart failure (one), atrial fibrillation (one), liver function test abnormalities (one), hyperglycemia (two), and thrombosis in one patient who did not receive 2-CdA. Severe neutropenia occurred in 10 patients, and all but two of the lowest absolute neutrophil counts were registered during treatment with CTX and prednisone (Table 3) . Severe thrombocytopenia was not seen in any patient during treatment with either CTX and prednisone or 2-CdA. There were no bleeding complications. Neutropenia was associated with severe infection in four patients (15%). Specific pathogens were not identified in these patients, and the clinical diagnosis of infection was based on neutropenic fever or pneumonia that improved
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Figure 1
Progression-free survival of previously untreated patients with chronic lymphocytic leukemia who had either a complete or a partial remission with combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in a sequential schedule.
with antibacterial therapy. With the exception of one patient with oral candidiasis, no opportunistic infections were documented.
Discussion and conclusions
In previously untreated CLL, the two frequently used PNAs (FAMP and 2-CdA) have been shown to induce CR and OR rates superior to those resulting from alkylator-based chemotherapy. 12, 13, 23 The fact that more than half of the best responses in the current study occurred only after additional treatment with 2-CdA supports such evidence. However, despite the added benefit of significantly longer duration of remission, a survival advantage for a PNA over conventional chemotherapy has yet to be realized. 10 In large cohorts of previously untreated patients with CLL, reported median remission durations of CR were 16.9 months (CR 45%) for 2-CdA with or without prednisone 24 and 37 months (CR 29%) for FAMP with or without prednisone. 10 The apparent difference in remission duration after 2-CdA vs FAMP treatment may be explained by the higher incidence of minimal residual disease that was demonstrated in 2-CdA-induced CR (67%) 24 vs FAMP-induced CR (11%). 25 Regardless, the majority of previously untreated patients with CLL who respond to singleagent therapy with a PNA have a relapse within 3 years, and there is no evidence of a survival plateau even in patients with true CR. 10 Because of different mechanisms of antitumor activity, 26 limited cross resistance, 27 and in vitro demonstration of synergistic cytotoxicity, 28 it was reasonable to explore the added advantage of combining alkylator-based chemotherapy with a PNA. However, the OR and CR rates seen in our two consecutive phase II studies that combined 2-CdA with alkylatorbased chemotherapy either concomitantly (OR 80%, CR 20%) 16 or sequentially (OR 96%, CR 33%) (the current study) were not substantially different from previously reported remission rates that had been achieved with single-agent 2-CdA with or without prednisone (OR 83%, CR 45%). 24 Similarly, the median duration of remission of CR in the current study (31 months) and the incidence of minimal residual disease in patients with CR (44%) were not particularly different Leukemia from those previously observed with either 2-CdA-or FAMPinduced CR. 24, 25 The absence of a long-term advantage for combined 2-CdA and alkylator-based chemotherapy is further suggested by an updated analysis of our initial phase II study 16 which showed less than 20% progression-free survival at a median follow-up of 61 months (Figure 2 ). The achievement of CR in this particular study did not affect either progressionfree survival or overall survival. Therefore, our experience from two consecutive phase II trials in previously untreated patients with CLL does not suggest a durable advantage for combined alkylator-based chemotherapy and 2-CdA over single-agent PNA alone.
A limited number of other studies have combined a PNA with treatment agents other than prednisone in patients with CLL. A combination of doxorubicin 29 or mitoxantrone 30 plus FAMP was abandoned early after unimpressive results in both previously untreated and treated patients with CLL. The results of phase I 15, 31, 32 and phase II 16 chlorambucil plus PNA combination trials have also not resulted in remission rates that were superior to those obtained from single-agent PNA therapy. In the only controlled study, 40 mg/m 2 of chlorambucil given every 4 weeks combined with 5 days of standard-dose FAMP treatment was not more effective than treatment with FAMP alone and resulted in increased toxicity. 12 More encouraging results have been obtained by combining FAMP with either epirubicin 33 or CTX. 34 In the former, OR and CR rates of 92% and 40%, respectively, were obtained in previously untreated patients with CLL. The corresponding remission rates in the latter were 94% and 44% and were comparable to historical controls that were treated with FAMP alone. 34 Some of the responses achieved in the latter study included patients who were refractory to single-agent fludarabine. The addition of supportive treatment with myeloid growth factors may further improve the tolerability of FAMP plus CTX combinations in previously untreated patients. 35 The merits of other combination schedules, including CTX and 2-CdA 36 or CTX and FAMP (currently ongoing NCCTG trial), remain to be seen. However, valid conclusions about the added benefit of a particular treatment approach can be made only on the basis of observations in a controlled setting.
The current study clearly shows a superior duration of remission associated with CR compared with PR. The improved progression-free survival and phenotypic remission
Figure 2
Progression-free survival of previously untreated patients with chronic lymphocytic leukemia who were treated with combination chemotherapy with chlorambucil and 2-chlorodeoxyadenosine in a concomitant schedule. rate associated with true CR have previously also been observed with single-agent therapy, with or without prednisone, with either FAMP 25 or 2-CdA. 24 Those results are different from those of a previous Eastern Cooperative Oncology Group (ECOG) study that compared alkylator-based chemotherapeutic regimens in CLL and did not show a difference in either duration of remission or survival between CR and PR states. 37 Nevertheless, the significantly longer duration of remission that has been associated with CR compared with PR has not yet translated into a survival advantage. 10 These observations suggest the need for refinement of the definition of CR if it is to be used as a surrogate end point for improved survival. In both the current study and the closely related previous phase II trial with a concomitant schedule, clinical stage, bone marrow infiltration pattern, or status of CD38 expression by CLL cells did not influence CR rate or progression-free survival (data not shown). A similar observation, in terms of clinical stage and bone marrow histology, has been made with single-agent PNA therapy in previously untreated patients with CLL. 10, 14 Recent information suggested the interrelationship and prognostic relevance of the mutational status of the immunoglobulin variable region and CD38 expression by CLL cells. 38 We were not, however, able to show a significant correlation between CD38 phenotype and either CR rate or progression-free survival in either of our two consecutive phase II trials.
